496 related articles for article (PubMed ID: 33995661)
21. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
22. A targeted and redox/pH-responsive chitosan oligosaccharide derivatives based nanohybrids for overcoming multidrug resistance of breast cancer cells.
Jia L; Li Z; Zheng D; Li Z; Zhao Z
Carbohydr Polym; 2021 Jan; 251():117008. PubMed ID: 33142574
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer.
Hu CM; Zhang L
Biochem Pharmacol; 2012 Apr; 83(8):1104-11. PubMed ID: 22285912
[TBL] [Abstract][Full Text] [Related]
24. Distinctive polymer micelle designed for siRNA delivery and reversal of MDR1 gene-dependent multidrug resistance.
Zhang CG; Yang SD; Zhu WJ; You BG; Liu Y; Yuan ZQ; Chen WL; Li JZ; Zhou XF; Liu C; Zhang XN
J Biomed Mater Res B Appl Biomater; 2017 Oct; 105(7):2093-2106. PubMed ID: 27405391
[TBL] [Abstract][Full Text] [Related]
25. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors.
Wang C; Guan W; Peng J; Chen Y; Xu G; Dou H
Acta Biomater; 2020 Feb; 103():247-258. PubMed ID: 31846802
[TBL] [Abstract][Full Text] [Related]
26. Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors.
Essex S; Navarro G; Sabhachandani P; Chordia A; Trivedi M; Movassaghian S; Torchilin VP
Gene Ther; 2015 Mar; 22(3):257-266. PubMed ID: 25354685
[TBL] [Abstract][Full Text] [Related]
27. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
28. Hyaluronan-Stabilized Redox-Sensitive Nanoassembly for Chemo-Gene Therapy and Dual T1/T2 MR Imaging in Drug-Resistant Breast Cancer Cells.
Rajendrakumar SK; Venu A; Revuri V; George Thomas R; Thirunavukkarasu GK; Zhang J; Vijayan V; Choi SY; Lee JY; Lee YK; Jeong YY; Park IK
Mol Pharm; 2019 May; 16(5):2226-2234. PubMed ID: 30924664
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic nanoparticles to combat cancer drug resistance.
Hu CM; Zhang L
Curr Drug Metab; 2009 Oct; 10(8):836-41. PubMed ID: 20214578
[TBL] [Abstract][Full Text] [Related]
30. Small molecules for great solutions: Can nitric oxide-releasing nanomaterials overcome drug resistance in chemotherapy?
Pieretti JC; Pelegrino MT; Nascimento MHM; Tortella GR; Rubilar O; Seabra AB
Biochem Pharmacol; 2020 Jun; 176():113740. PubMed ID: 31786262
[TBL] [Abstract][Full Text] [Related]
31. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
Gote V; Nookala AR; Bolla PK; Pal D
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
[TBL] [Abstract][Full Text] [Related]
32. Marine Natural Products as Models to Circumvent Multidrug Resistance.
Long S; Sousa E; Kijjoa A; Pinto MM
Molecules; 2016 Jul; 21(7):. PubMed ID: 27399665
[TBL] [Abstract][Full Text] [Related]
33. Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer.
Mohammad IS; Teng C; Chaurasiya B; Yin L; Wu C; He W
Int J Pharm; 2019 Feb; 557():304-313. PubMed ID: 30599232
[TBL] [Abstract][Full Text] [Related]
34. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
35. Co-delivery strategies to overcome multidrug resistance in ovarian cancer.
Khan IU; Khan RU; Asif H; Alamgeer ; Khalid SH; Asghar S; Saleem M; Shah KU; Shah SU; Rizvi SAA; Shahzad Y
Int J Pharm; 2017 Nov; 533(1):111-124. PubMed ID: 28947245
[TBL] [Abstract][Full Text] [Related]
36. Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance.
Liu J; Ye Z; Xiang M; Chang B; Cui J; Ji T; Zhao L; Li Q; Deng Y; Xu L; Wang G; Wang L; Wang Z
Biomaterials; 2019 Dec; 223():119475. PubMed ID: 31520888
[TBL] [Abstract][Full Text] [Related]
37. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
[TBL] [Abstract][Full Text] [Related]
38. Near-infrared light switching nitric oxide nanoemitter for triple-combination therapy of multidrug resistant cancer.
Wei G; Yang G; Wei B; Wang Y; Zhou S
Acta Biomater; 2019 Dec; 100():365-377. PubMed ID: 31586724
[TBL] [Abstract][Full Text] [Related]
39. [Research progress in co-delivery of gene and chemotherapy drugs with nanocarriers for cancer therapy].
Chen WG; Wang SB
Yao Xue Xue Bao; 2013 Jul; 48(7):1091-8. PubMed ID: 24133974
[TBL] [Abstract][Full Text] [Related]
40. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
Tiash S; Chowdhury EH
J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
